Author: Rangsinth, Panthakarn; Sillapachaiyaporn, Chanin; Nilkhet, Sunita; Tencomnao, Tewin; Ung, Alison T.; Chuchawankul, Siriporn
Title: Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach Cord-id: lhbl6fdl Document date: 2021_1_4
ID: lhbl6fdl
Snippet: BACKGROUND AND AIM: Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now become the world pandemic. There is a race to develop suitable drugs and vaccines for the disease. The anti-HIV protease drugs are currently repurposed for the potential treatment of COVID-19. The drugs were primarily screened against the SARS-CoV-2 main protease. With an urgent need for safe and effective drugs to treat the virus, we have explored natural produc
Document: BACKGROUND AND AIM: Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now become the world pandemic. There is a race to develop suitable drugs and vaccines for the disease. The anti-HIV protease drugs are currently repurposed for the potential treatment of COVID-19. The drugs were primarily screened against the SARS-CoV-2 main protease. With an urgent need for safe and effective drugs to treat the virus, we have explored natural products isolated from edible and medicinal mushrooms that have been reported to possess anti-HIV protease. EXPERIMENTAL PROCEDURES: We have examined 36 compounds for their potential to be SARS-CoV-2 main protease inhibitors using molecular docking study. Moreover, drug-likeness properties including absorption, distribution, metabolism, excretion and toxicity were evaluated by in silico ADMET analysis. RESULTS: Our AutoDock study showed that 25 of 36 candidate compounds have the potential to inhibit the main viral protease based on their binding affinity against the enzyme’s active site when compared to the standard drugs. Interestingly, ADMET analysis and toxicity prediction revealed that 6 out of 25 compounds are the best drug-like property candidates, including colossolactone VIII, colossolactone E, colossolactone G, ergosterol, heliantriol F and velutin. CONCLUSION: Our study highlights the potential of existing mushroom-derived natural compounds for further investigation and possibly can be used to fight against SARS-CoV-2 infection. TAXONOMY (CLASSIFICATION BY EVISE): Disease, Infectious Disease, Respiratory System Disease, Covid-19, Traditional Medicine, Traditional Herbal Medicine, Phamaceutical Analysis.
Search related documents:
Co phrase search for related documents- acute respiratory distress syndrome and low toxicity: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory distress syndrome respiratory disease and low binding: 1
- acute respiratory distress syndrome respiratory disease and low binding energy: 1
- acute respiratory distress syndrome respiratory disease and low toxicity: 1
- acute respiratory distress syndrome respiratory disease and lung inflammation: 1, 2, 3
- acute respiratory syndrome and adme analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory syndrome and adme excretion metabolism distribution: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory syndrome and adme excretion metabolism distribution absorption: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory syndrome and liver skin: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome and low binding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- acute respiratory syndrome and low binding energy: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome and low toxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- acute respiratory syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute sars cov respiratory syndrome coronavirus and adme analysis: 1, 2, 3, 4, 5, 6, 7, 8
- acute sars cov respiratory syndrome coronavirus and adme excretion metabolism distribution: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute sars cov respiratory syndrome coronavirus and adme excretion metabolism distribution absorption: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute sars cov respiratory syndrome coronavirus and liver skin: 1, 2, 3, 4, 5
- acute sars cov respiratory syndrome coronavirus and low binding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
Co phrase search for related documents, hyperlinks ordered by date